Fresenius Kabi announced the launch of Cisatracurium Besylate Injection, the generic equivalent of AbbVie’s Nimbex.

Nimbex is approved for inpatient and outpatient use as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the intensive care unit (ICU). Cisatracurium Besylate is an intermediate-onset and intermediate-duration neuromuscular blocker that binds competitively to cholinergic receptor sites to antagonize the action of acetylcholine; this results in the block of neuromuscular transmission.

RELATED: Gender Differences Seen With Cognitive Decline Post-Anesthesia

Cisatracurium Besylate injection will be available as a 10mg/5mL single-use vial, 20mg/10mL multi-dose vial, and 200mg/20mL single-use vial.

For more information visit